ACADIA Pharmaceuticals Inc. (ACAD)
NASDAQ: ACAD · Real-Time Price · USD
25.61
-0.26 (-1.01%)
At close: Aug 3, 2026, 4:00 PM EDT
25.29
-0.32 (-1.25%)
After-hours: Aug 3, 2026, 7:34 PM EDT
ACADIA Pharmaceuticals Revenue
ACADIA Pharmaceuticals had revenue of $268.06M in the quarter ending March 31, 2026, with 9.72% growth. This brings the company's revenue in the last twelve months to $1.10B, up 9.93% year-over-year. In the year 2025, ACADIA Pharmaceuticals had annual revenue of $1.07B with 11.87% growth.
Revenue (ttm)
$1.10B
Revenue Growth
+9.93%
P/S Ratio
4.00
Revenue / Employee
$1,372,494
Employees
798
Market Cap
4.39B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.07B | 113.71M | 11.87% |
| Dec 31, 2024 | 957.80M | 231.36M | 31.85% |
| Dec 31, 2023 | 726.44M | 209.20M | 40.45% |
| Dec 31, 2022 | 517.24M | 33.09M | 6.83% |
| Dec 31, 2021 | 484.15M | 42.39M | 9.60% |
| Dec 31, 2020 | 441.76M | 102.68M | 30.28% |
| Dec 31, 2019 | 339.08M | 115.27M | 51.50% |
| Dec 31, 2018 | 223.81M | 98.91M | 79.19% |
| Dec 31, 2017 | 124.90M | 107.57M | 620.68% |
| Dec 31, 2016 | 17.33M | 17.27M | 28,311.48% |
| Dec 31, 2015 | 61.00K | -59.00K | -49.17% |
| Dec 31, 2014 | 120.00K | -1.03M | -89.52% |
| Dec 31, 2013 | 1.15M | -3.76M | -76.67% |
| Dec 31, 2012 | 4.91M | 2.84M | 137.40% |
| Dec 31, 2011 | 2.07M | -40.07M | -95.09% |
| Dec 31, 2010 | 42.14M | 35.74M | 558.46% |
| Dec 31, 2009 | 6.40M | 4.81M | 302.45% |
| Dec 31, 2008 | 1.59M | -5.97M | -78.95% |
| Dec 31, 2007 | 7.56M | -578.00K | -7.11% |
| Dec 31, 2006 | 8.13M | -2.82M | -25.77% |
| Dec 31, 2005 | 10.96M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Caris Life Sciences | 907.29M |
| Travere Therapeutics | 536.20M |
| Tango Therapeutics | 56.99M |
| Relay Therapeutics | 10.68M |
| CRISPR Therapeutics AG | 4.10M |
ACAD News
- 4 days ago - Acadia Pharmaceuticals to Participate in the Canaccord Genuity 46th Annual Growth Conference - Business Wire
- 13 days ago - Acadia Pharmaceuticals price target raised to $36 from $34 at BMO Capital - TheFly
- 13 days ago - Acadia Pharmaceuticals price target raised to $25 from $24 at Stifel - TheFly
- 14 days ago - Acadia Pharmaceuticals price target raised to $25 from $24 at Stifel - TheFly
- 14 days ago - Acadia Pharmaceuticals receives FDA Fast Track designation for remlifanserin - TheFly
- 14 days ago - Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis - Business Wire
- 19 days ago - Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026 - Business Wire
- 27 days ago - Acadia Pharmaceuticals price target raised to $36 from $29 at RBC Capital - TheFly